Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer

Aya Abunada; Zaid Sirhan; Anita Thyagarajan; Ravi P Sahu

doi:10.5306/wjco.v14.i5.198

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer

World J Clin Oncol. 2023 May 24;14(5):198-202. doi: 10.5306/wjco.v14.i5.198.

Authors

Aya Abunada¹, Zaid Sirhan², Anita Thyagarajan², Ravi P Sahu³

Affiliations

¹ Department of Pharmacy, Sidra Medicine, Doha 0000, Qatar.
² Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Dayton, OH 45435, United States.
³ Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Dayton, OH 45435, United States. ravi.sahu@wright.edu.

Abstract

The body of evidence investigating human epidermal growth factor receptor-2 (HER2) directed therapy in patients with breast cancer (BC) has been growing within the last decade. Recently, the use of tyrosine kinase inhibitors (TKIs) has been of particular interest in the treatment of human malignancies. This literature commentary is intended to highlight the most recent findings associated with the widely-studied TKI agents and their clinical significance in improving the outcomes of HER2 positive BC.

Keywords: Human epidermal growth factor receptor-2 positive breast cancer; Lapatinib; Pyrotinib; Trastuzumab; Tucatinib; Tyrosine kinase inhibitors.

Publication types

Review